Mesa Laboratories Inc. 10-Q Summary
Business Context and Reporting Period
Mesa Laboratories, Inc. manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, medical sterilization, and pharmaceutical processing. This report covers the quarterly period ended September 30, 2008 (Q2 Fiscal 2009) and the six months ended September 30, 2008.
Key Financial Metrics
| Metric | Q2 2008 (3 Months) | Q2 2007 (3 Months) | YTD 2008 (6 Months) | YTD 2007 (6 Months) |
|---|---|---|---|---|
| Net Sales | $5,679,000 | $4,868,000 | $10,734,000 | $9,154,000 |
| Gross Margin | 64.2% | 67.5% | 63.8% | 67.6% |
| Net Income | $1,353,000 | $1,279,000 | $2,370,000 | $2,294,000 |
| Diluted EPS | $0.42 | $0.39 | $0.73 | $0.70 |
| Operating Cash Flow | N/A | N/A | $1,885,000 | $2,427,000 |
| Cash & Equivalents | $6,728,000 | $4,722,000 | $6,728,000 | $4,722,000 |
| Total Debt | $0 | $0 | $0 | $0 |
| Current Ratio | 12.4:1 | 9.1:1 | 12.4:1 | 9.1:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% year-over-year for both the quarter and the six-month period. Product sales grew 19% YTD, driven by the DataTrace and Raven product lines.
- Margin Compression: Gross margins declined from 67.5% to 64.2% in Q2 and from 67.6% to 63.8% YTD. This was attributed to a shift in product mix toward lower-margin Raven chemical indicators (margins 15-30%) and higher sales of lower-margin OEM products.
- Expense Increases: Selling, General & Administrative (SG&A) expenses rose due to Sarbanes-Oxley compliance costs and the addition of a Controller. Research and Development (R&D) spending increased 51% YTD ($333,000 vs $200,000) to support new product development.
- Liquidity: Cash and cash equivalents increased by $958,000 during the six-month period. The company maintains a debt-free balance sheet with a current ratio of 12.4:1.
Guidance, Outlook, and Risks
Management Commentary: Management notes that while economic conditions have softened, the company has seen little impact on sales due to the resilience of its target industries (medical, food, pharmaceutical). Profitability trends are showing some decline due to growth investments and lower profitability percentages on specific product lines. The company is investing in automation for its Raven operations, with benefits expected in the latter part of the third quarter.
Capital Allocation: The company continues a share repurchase program (up to 300,000 shares authorized) and pays regular quarterly dividends ($0.10 per share). No line of credit or debt is currently maintained.
Risks and Contingencies: Key risks include competition in data logging, kidney dialysis, and biological indicator markets; changes in capital spending trends; and the potential discontinuance of dialyzer reuse practices. The filing states there have been no material changes to risk factors from the previous 10-K.
Investor Verification Checklist
- Product Mix Impact: Verify the sustainability of the shift toward lower-margin Raven chemical indicators and its long-term effect on gross margins.
- R&D ROI: Monitor the commercial success of the new DataTrace Micropack RF product to justify the 51% increase in R&D spending.
- Automation Benefits: Confirm the timeline and cost savings realization from the $575,000 equipment purchase for Raven manufacturing automation.
- Share Count: Track the impact of the ongoing share repurchase program (111,015 shares purchased to date) on earnings per share.
- Interest Income: Assess the impact of softening interest rates on the company's surplus cash investment income.